Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3

Summary

The primary objective of the study is to demonstrate that the efficacy of peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naïve patients with chronic hepatitis C virus infection genotype 2 or 3 given for 12 weeks is non-inferior to 24 weeks.

Timeline

Start

2004-04

Primary completion

—

Completion

2006-10

Publications

• Waldenstrom J, Hellstrand K, Westin J, Nilsson S, Christensen P, Farkkila M, Morch K, Langeland N, Norkrans G, Lagging M. Presence of interferon-lambda 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. Scand J Gastroenterol. 2021 Jul;56(7):849-854. doi: 10.1080/00365521.2021.1922750. Epub 2021 Jun 2.

Drugs

Indications